154 related articles for article (PubMed ID: 37072054)
21. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
22. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
[TBL] [Abstract][Full Text] [Related]
23. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
24. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
Lauring AS; Tenforde MW; Chappell JD; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Adams K; Schrag SJ; Olson SM; Kobayashi M; Verani JR; Patel MM; Self WH;
BMJ; 2022 Mar; 376():e069761. PubMed ID: 35264324
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19.
Kapur R; Okumura K; Feola N; Keller M; Dhand A
Cureus; 2023 May; 15(5):e38867. PubMed ID: 37313067
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Omicron and its current known unknowns: A narrative review.
Le TTB; Vasanthakumaran T; Thi Hien HN; Hung IC; Luu MN; Khan ZA; An NT; Tran VP; Lee WJ; Abdul Aziz JM; Ali T; Dumre SP; Huy NT
Rev Med Virol; 2023 Jan; 33(1):e2398. PubMed ID: 36150052
[TBL] [Abstract][Full Text] [Related]
27. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
[TBL] [Abstract][Full Text] [Related]
28. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
[TBL] [Abstract][Full Text] [Related]
29. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
[TBL] [Abstract][Full Text] [Related]
30. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
31. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
32. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
[TBL] [Abstract][Full Text] [Related]
34. The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants.
Gershengorn HB; Patel S; Ferreira T; Das S; Parekh DJ; Shukla B
PLoS One; 2022; 17(12):e0278770. PubMed ID: 36459537
[TBL] [Abstract][Full Text] [Related]
35. Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Beraud G; Bouetard L; Civljak R; Michon J; Tulek N; Lejeune S; Millot R; Garchet-Beaudron A; Lefebvre M; Velikov P; Festou B; Abgrall S; Lizatovic IK; Baldolli A; Esmer H; Blanchi S; Froidevaux G; Kapincheva N; Faucher JF; Duvnjak M; Afşar E; Švitek L; Yarimoglu S; Yarimoglu R; Janssen C; Epaulard O;
Clin Microbiol Infect; 2023 May; 29(5):642-650. PubMed ID: 36587737
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 reinfections in the pediatric cohort-a single-center experience.
Arslan A; Sahbudak Bal Z; Erci E; Yıldırım Arslan S; Bilen NM; Avcu G; Çiçek C; Ozkinay F; Kurugol Z
J Trop Pediatr; 2023 Dec; 70(1):. PubMed ID: 38150674
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
38. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).
Ciuffreda L; Lorenzo-Salazar JM; García-Martínez de Artola D; Gil-Campesino H; Alcoba-Florez J; Rodríguez-Pérez H; Íñigo-Campos A; Salas-Hernández J; Rodríguez-Nuñez J; Muñoz-Barrera A; Valenzuela-Fernández A; Díez-Gil O; González-Montelongo R; Flores C
Emerg Microbes Infect; 2023 Dec; 12(1):2202281. PubMed ID: 37039029
[No Abstract] [Full Text] [Related]
39. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
Havers FP; Patel K; Whitaker M; Milucky J; Reingold A; Armistead I; Meek J; Anderson EJ; Weigel A; Reeg L; Seys S; Ropp SL; Spina N; Felsen CB; Moran NE; Sutton M; Talbot HK; George A; Taylor CA;
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(34):1085-1091. PubMed ID: 36006841
[TBL] [Abstract][Full Text] [Related]
40. Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19.
Voor In 't Holt AF; Haanappel CP; Rahamat-Langendoen J; Molenkamp R; van Nood E; van den Toorn LM; Peeters RP; van Rossum AMC; Severin JA
Int J Infect Dis; 2022 Sep; 122():665-668. PubMed ID: 35842214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
